Timothy E. Askew
Mr. Askew co-owns HV PharmaLabs & HV Pharmacy, Inc. (“HVP”) with Brian H. Trentler, R.Ph. HVP is a 33-year provider of custom, branded, and generic medications to patients and physician practices in the mid-Atlantic region. Focusing on providing custom sterile medications and biologics for ophthalmology, HVP operates as a high-quality manufacturer of customized medications and biological therapies. HVP owns the brands NovoTears™, OP Drops™, and Stat Drops™.
Prior to HVP Mr. Askew was President/CEO of Tissue Banks International, the largest integrated ocular, musculoskeletal, and dermis processor and distributor in the world. With over 50 owned and affiliated facilities around the world, TBI recovers, processes, and distributes a wide range of biological implants to thousands of physicians with exacting standards. TBI works with physicians, tissue engineers, and scientists to create innovative allografts and live-cell implants for spine, orthopedic, sports medicine, dermis, and ocular applications.
Prior to TBI, Mr. Askew was President/CEO and Chairman of CSA Medical, Inc., a privately held medical device technology company dedicated to pioneering the TruFreezeTM platform to eradicate pre-cancerous and cancerous tissues. TruFreeze is a patented treatment platform currently in use at the top cancer centers in the US. At CSA Medical, Mr. Askew has raised over $20 million of private equity capital and led the company through numerous regulatory, clinical, product development, staffing, and commercialization milestones. CSA Medical is currently commercializing a novel therapy to treat chronic bronchitis.
Mr. Askew is very active in the Baltimore/DC medical technology space. He currently works with a wide range of medical device ventures in the Mid-Atlantic region, serving as in investor, board member, advisor, mentor, and consultant.
A graduate of the University of Michigan where he studied a pre-med curriculum, he received his MBA from Boston University in 1989. Mr. Askew has published papers in Circulation-Journal of the American Heart Association and has a patent for a compound he developed along with multiple patents in process at the USPTO.
Mr. Askew also donates his time as a reviewer for the Maryland Innovation Initiative and as a member of the Coulter Foundation Oversight Committee at the Johns Hopkins University Center for Bioengineering Innovation and Design. He is also an active member in the Central Maryland Beekeepers Association.